Market Closed -
NSE India S.E.
07:43:48 2024-05-03 am EDT
5-day change
1st Jan Change
1,338
INR
-0.98%
-0.06%
+20.17%
Sales 2024 *
75.75B
909M
Sales 2025 *
89.01B
1.07B
Capitalization
339B
4.07B
Net income 2024 *
6.32B
75.8M
Net income 2025 *
9.52B
114M
EV / Sales 2024 *
4.62
x
Net Debt
2024
*
10.55B
127M
Net Debt
2025
*
4.59B
55.04M
EV / Sales 2025 *
3.86
x P/E ratio 2024 *
54.3
x
P/E ratio 2025 *
35.5
x
Employees
16,167
Yield 2024 *
0.35%
Yield 2025 *
0.43%
Free-Float
52.35%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director
Mar. 29
CI
Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director
Mar. 29
CI
Ipca Laboratories Licenses Anti-Cancer Biosimilar Technology to Omexa Formulary
Mar. 27
MT
Ipca Laboratories Limited Enters into A Technology Transfer Agreement with Omexa Formulary Pvt. Ltd
Mar. 27
CI
Nomura Adjusts IPCA Laboratories Price Target to INR1,308 From INR1,113, Keeps at Buy
Feb. 19
MT
Transcript : Ipca Laboratories Limited, Q3 2024 Earnings Call, Feb 15, 2024
Feb. 15
Ipca Laboratories Limited Announces Appointment of Kamal Kishore Seth as the Lead Independent Director
Feb. 14
CI
Ipca Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Feb. 14
CI
Transcript : Ipca Laboratories Limited, Q2 2024 Earnings Call, Nov 10, 2023
Nov. 10
Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2023-24
Nov. 10
CI
Ipca Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Nov. 10
CI
Ipca Laboratories' Pithampur Plant Classified as VAI by US FDA
23-10-31
MT
Nomura Upgrades Ipca Laboratories to Buy From Neutral, Adjusts Price Target to INR1,133 From INR942
23-10-23
MT
INDIA STOCKS-Indian shares slide on Mideast jitters; ICICI Bank up on earnings beat
23-10-23
RE
Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)
23-10-16
CI
More news
1 day -0.98%
1 week -0.06%
Current month -0.13%
1 month +1.76%
3 months +17.93%
6 months +37.94%
Current year +20.17%
More quotes
Managers
Title Age Since
Chief Executive Officer
68
80-04-01
Chief Executive Officer
51
03-04-15
Chairman
77
75-10-30
Members of the board
Title Age Since
Chairman
77
75-10-30
Director/Board Member
76
11-08-15
Chief Executive Officer
51
03-04-15
More insiders
Date
Price
Change
Volume
24-05-03
1,338
-0.98%
278,430
24-05-02
1,351
+0.86%
291,150
24-04-30
1,340
+0.41%
358,148
24-04-29
1,334
-0.34%
384,574
Delayed Quote
NSE India S.E., May 03, 2024 at 07:43 am EDT
More quotes
Ipca Laboratories Limited is an India-based pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIâs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
More about the company
Last Close Price
1,338
INR
Average target price
1,163
INR
Spread / Average Target
-13.05%
Consensus
1st Jan change
Capi.
+20.17% 4.07B +26.08% 662B +21.85% 546B -4.77% 359B +16.97% 323B +5.69% 290B +13.68% 234B +3.65% 198B -11.12% 194B +8.08% 167B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1